1. Introduction {#s0005}
===============

The most common neglected tropical diseases (NTDs) are the soil-transmitted helminths (STH) which include *Ascaris lumbricoides*, *Trichuris trichiura* and the hookworms ([@bb0180]). The mainstay of the control of STH is regular preventive chemotherapy using either albendazole or mebendazole. Control programmes largely target these treatments at school-aged children (SAC) and preschool-aged children (Pre-SAC). In the majority of endemic areas, treatment is given annually, but in areas of intense transmission (defined as a prevalence of any STH greater than 50% in SAC), the WHO recommends that the treatment frequency is increased to at least twice a year (depending on resource availability) ([@bb0250]). The aim of these WHO guidelines is to reduce the prevalence of heavy infections and their associated morbidity ([@bb0255]).

However, although both albendazole and mebendazole have a high efficacy against *A. lumbricoides* (with cure rates above 78%), mebendazole does not effectively clear hookworm infections, and neither drug has an adequate efficacy against *T. trichiura (*[@bb0120], [@bb0240], [@bb0140]) (albendazole has a cure rate of 28% (95% CI: 13%--39%) and mebendazole 36% (95% CI: 16%--51%) ([@bb0120])). This considerably lower efficacy of the standard treatments limits the overall possible effectiveness of preventive chemotherapy against *T. trichiura*, which is estimated to infect 464.6 million people worldwide (mainly in sub-Saharan Africa and Asia but also in parts of Latin America ([@bb0185])). Heavy *T. trichiura* infections can lead to severe anaemia, growth retardation, and impaired cognitive development ([@bb0060]). In addition to these clinical and nutritional impacts, *T. trichiura* may have effects on the physical fitness of children ([@bb0265]).

In addition to the goals of reducing morbidity, there is growing interest in investigating the feasibility of interrupting transmission of STH ([@bb0100], [@bb0055], [@bb0030]) --- although this is not yet the aim of current World Health Organisation (WHO) policy. In this regard, the poor treatment efficacy of albendazole and mebendazole against *T. trichiura* may hinder the success of STH elimination programmes as a whole --- as residual *T. trichiura* infection may remain after the transmission of *A. lumbricoides* and hookworm is interrupted.

The impact of a STH control programme on *T. trichiura* may be enhanced by adding ivermectin to the treatment schedule. This approach has been demonstrated to significantly increase the treatment efficacy of both standalone albendazole and mebendazole against *T. trichiura* ([@bb0130], [@bb0040], [@bb0045], [@bb0195]). Ivermectin is an anthelmintic which Merck & Co donate for the control of onchocerciasis and lymphatic filariasis ([@bb0005]).

In this paper we use mathematical models of STH transmission ([@bb0200], [@bb0205], [@bb0025], [@bb0235]) to evaluate the following factors; 1) the additional programmatic impact gained by co-administering ivermectin in terms of reducing mean worm burden, prevalent infections, and the prevalence of heavy infections; and 2) how ivermectin co-administration may influence the feasibility of interrupting the transmission of *T. trichiura*.

2. Methods {#s0010}
==========

This analysis was performed using a fully age-structured deterministic model of the dynamics of STH transmission including simulation of parasite sexual reproduction ([@bb0200], [@bb0205], [@bb0025], [@bb0235]). In this paper we used the model parameters pertaining to *T. trichiura* which are described in more detail in the Supporting Table S1. It should be noted that the individuals treated each round are effectively chosen at random from the relevant age group(s) and the model does not currently address systematic non-compliance. A future publication will examine this issue in more detail using an individual-based stochastic model.

2.1. Fitted setting {#s0015}
-------------------

The model parameters describing the age-specific exposure and contribution to the infection reservoir and level of transmission (R~0~) were estimated by fitting to data from the cross-sectional study of *T. trichiura* conducted in St. Lucia by [@bb0065] ([Fig. 1](#f0005){ref-type="fig"}). The study collected pre-treatment and post-treatment stool samples from 119 individuals across a full range of ages. The resulting data set contains a record for each individual consisting of age, eggs per gramme (EPG) of faeces and expelled worm burden. We estimated that in this setting, the overall R~0~ for the whole community was 1.75 (reported R~0~ estimates for *T. trichiura* often relate to the R~0~ for children only and are therefore higher).Fig. 1Model fit to cross-sectional data from the St. Lucia study ([@bb0065]). Note that the model fit was done to the individual data points and not the average data values shown here (see Supporting Information and Supporting Fig. 1).Fig. 1

The age profile of infection intensity ([Fig. 1](#f0005){ref-type="fig"}) is very consistent to that reported by a recent systematic review of epidemiological surveys of STH in Southeast Asia ([@bb0095]).

2.2. Treatment efficacy {#s0020}
-----------------------

The model describes changes in the mean worm burden over time and age. Treatment impact within the model is defined in terms of the proportion of worms expelled after treatment. The efficacy values used (see below) are based on observed faecal egg reduction rates (ERRs) and not cure rates (the percentage of individuals who became helminth egg negative following treatment with an anthelmintic drug). The ERR of standalone albendazole (400 mg) was assumed to be 50% ([@bb0240]) and the ERR of albendazole--ivermectin co-administration was assumed to be 95%, based on a recent randomized controlled trial by [@bb0195]. This is consistent with a different trial which reported a similar ERR of 91% ([@bb0130]). The impact of using mebendazole--ivermectin combination therapy was also considered within the sensitivity analysis ([@bb0130]). Within this scenario, the ERR of standalone mebendazole (500 mg) was assumed to be 63% ([@bb0140]) and mebendazole--ivermectin co-administration to be 97%, based on the trial by [@bb0130].

Children under 15 kg in weight or 90 cm in height (generally under five years of age ([@bb0105])) are ineligible to receive ivermectin ([@bb0250]) and were assumed to have only received albendazole or mebendazole. Individuals under one years of age were assumed to be ineligible for mebendazole treatment and individuals under two years of age ineligible for albendazole (400 mg) treatment. Though one year olds are sometimes provided a lower dose of albendazole (200 mg) ([@bb0250]), this was not included in the model as the precise efficacy of this lower dose is unknown.

2.3. Programmatic scenarios and output {#s0025}
--------------------------------------

The model was used to simulate a programme targeting Pre-SAC and SAC, following WHO guidelines ([@bb0260]), and to compare standalone treatment to ivermectin co-administration using three different effectiveness metrics (described in [@bb0235] work): 1) the total number of worm years averted (i.e. a year lived with a worm), 2) the total number of prevalent infection case years averted (i.e. the number of years lived with a prevalent infection prevented --- not adjusted for diagnostic sensitivity), and 3) total number of heavy infection case years averted (i.e. the number of years lived with heavy infection prevented). Heavy infection was defined as having a worm burden above the age-specific thresholds for disease described in [Table 1](#t0005){ref-type="table"} (as defined in [@bb0075] work and the 2010 Global Burden of Disease study ([@bb0185])). It is important to note that the relationships between STH infection burdens (present and/or past) and morbidity are complex and not well understood ([@bb0050]). We employed published estimates as detailed in [Table 1](#t0005){ref-type="table"}.Table 1Age-specific worm burden thresholds for heavy infections (a proxy for morbidity) ([@bb0075], [@bb0070]).Table 1Age class (years)Number of worms --- lower thresholdNumber of worms --- higher threshold0--4902505--913037510 +180500[^1]

In addition to the fitted transmission setting (R~0~ = 1.75), we also explored a setting with lower transmission (R~0~ = 1.25). These stratifications for transmission settings differ somewhat from the WHO prevalence categories for reasons described in [@bb0200] work. These R~0~\'s are different to previous studies on hookworm and *A. lumbricoides* ([@bb0200], [@bb0205], [@bb0025], [@bb0235]) due to the difference in the level of density dependence acting on female worm fecundity (Supporting Table S1). The sensitivity of the relative impact of ivermectin co-administration to different treatment coverage levels was also explored.

In addition to the increased programmatic impact regarding control of *T. trichiura*, the model was used to compare the feasibility of breaking transmission for each of the different treatment regimens, as well as the timespans required to do so. Breaking transmission is theoretically possible when worm levels are driven low enough that the probability of a female worm not encountering a mate in its host crosses a critical value. Below this, fertile egg production falls so low that the parasite population as a whole cannot be sustained (the so called 'breakpoint', [@bb0020]).

3. Results {#s0030}
==========

3.1. Controlling morbidity {#s0035}
--------------------------

When using standalone albendazole (monotherapy), annual targeted PC (Pre-SAC and SAC) elicited only a gradual reduction in the overall mean worm burden of *T. trichiura* ([Fig. 2](#f0010){ref-type="fig"}).Fig. 2Projected impact of annual and biannual targeted preventive chemotherapy with and without ivermectin co-administration on the mean worm burden of *T. trichiura*. The solid and dotted line pertain to standalone albendazole, and albendazole--ivermectin co-administration respectively. Two different transmission settings were explored; lower (R~0~ = 1.25), and higher (R~0~ = 1.75 --- fitted). Results assume 75% treatment coverage of Pre-SAC and SAC. The drug efficacy was assumed to be 50% for standalone albendazole ([@bb0240]), and 95% when co-administering ivermectin ([@bb0195]). Note that those under five years of age cannot receive ivermectin and would only be treated with albendazole. ALB; Albendazole, IVM; Ivermectin.Fig. 2

In lower transmission settings annual albendazole monotherapy at a high coverage (75%) was projected to be sufficient in controlling heavy infections in children ([Fig. 3](#f0015){ref-type="fig"} and Supporting Fig. S2). However, these simulations indicate that in the fitted (higher) transmission settings annual albendazole monotherapy may be insufficient to fully control the prevalence of heavy infections ([Fig. 3](#f0015){ref-type="fig"} and Supporting Fig. S2). The impact of albendazole monotherapy on heavy infections was greater, the higher the intensity threshold for heavy infection ([Fig. 3](#f0015){ref-type="fig"} and Supporting Fig. S2).Fig. 3Projected impact of annual and biannual targeted preventive chemotherapy with and without ivermectin co-administration on the prevalence of heavy *T. trichiura* infections in children. The solid and dotted line pertain to standalone albendazole, and albendazole--ivermectin co-administration respectively. Two different transmission settings were explored; lower (R~0~ = 1.25), and higher (R~0~ = 1.75 --- fitted). Results assume 75% treatment coverage of Pre-SAC and SAC. The drug efficacy was assumed to be 50% for standalone albendazole ([@bb0240]), and 95% when co-administering ivermectin ([@bb0195]). Note that those under five years of age cannot receive ivermectin and would only be treated with albendazole. The results assume the lower intensity thresholds for heavy infection (presented in [Table 1](#t0005){ref-type="table"}). The corresponding results using the higher intensity threshold are presented in Supporting Fig. S2. ALB; Albendazole, IVM; Ivermectin.Fig. 3

Ivermectin co-administration increased the projected impact of the programme in terms of all three of the explored metrics; worm burden, prevalent case years, and heavy infection case years, especially in high transmission settings ([Table 2](#t0010){ref-type="table"}). Of particular note, in a high transmission setting co-administering ivermectin increased the number of heavy infection case years averted by 36% (when using the lower intensity threshold ([Table 1](#t0005){ref-type="table"})). Although, some heavy infections may remain if treatment is only given annually ([Fig. 3](#f0015){ref-type="fig"}).Table 2Programmatic impact in terms of the worm burden reduced, prevalent case years averted, and heavy infection case years averted, when treating with and without ivermectin co-administration.Table 2Treatment strategyWorm years averted (per 100)Prevalent case years averted (per 100)Heavy infection case years averted --- lower threshold[a](#tf0005){ref-type="table-fn"} (per 100)Heavy infection case years averted --- higher threshold[a](#tf0005){ref-type="table-fn"} (per 100)*Fitted (higher) transmission setting*Standalone albendazole Annual targeted treatment24,290525519 Biannual targeted treatment35,7331587822Ivermectin co-administration Annual targeted treatment33,6531187522 Biannual targeted treatment40,9813908423  *Lower transmission setting*Standalone albendazole Annual targeted treatment8,99521812.8880.512 Biannual targeted treatment10,05527613.3530.517Ivermectin co-administration Annual targeted treatment10,00527513.3550.517 Biannual targeted treatment10,85836313.5380.518[^2][^3]

If ivermectin (or another alternative treatment) could be given to Pre-SAC, the relative impact on heavy infections averted in a high transmission setting would further increase from 36% to 52% ([Fig. 4](#f0020){ref-type="fig"} and Supporting Fig. S3) --- when using the lower intensity threshold ([Table 1](#t0005){ref-type="table"}).Fig. 4Impact of a child-targeted preventive chemotherapy in terms of heavy case years averted with and without ivermectin co-administration. The bars are stratified by the host age-group (from the bottom up: Infants (0--2 year olds), Pre-SAC (2--5 year olds), SAC (5--15 year olds), and Adults (≥ 15 year olds)). Results pertain to the fitted (higher) transmission setting (R~0~ = 1.75 --- fitted) and assume 75% treatment coverage of Pre-SAC and SAC. The analysis was performed with a ten year time horizon (comparing ten years of standalone treatment to ivermectin co-administration). The drug efficacy was assumed to be 50% for standalone albendazole ([@bb0240]), and 95% when co-administering ivermectin ([@bb0195]). The results assume the lower intensity thresholds for heavy infection (presented in [Table 1](#t0005){ref-type="table"}). The corresponding results using the higher intensity threshold are presented in Supporting Fig. S3. ALB; Albendazole, IVM; Ivermectin.Fig. 4

In both explored transmission settings, the impact to annual ivermectin co-administration was comparable to that of increasing the treatment frequency of albendazole monotherapy to twice a year ([Table 2](#t0010){ref-type="table"}). Biannual treatment is recommended by the WHO in high risk settings, if the resources are available --- which is not always the case ([@bb0250]). Even with biannual standalone treatment at a high coverage some heavy infections were projected to remain ([Fig. 3](#f0015){ref-type="fig"}). Consequently, even if biannual treatment were feasible, co-administering ivermectin (for both rounds) would still be beneficial in some settings ([Fig. 3](#f0015){ref-type="fig"} and [Table 2](#t0010){ref-type="table"}).

The assumed level of treatment coverage did not greatly influence the relative increase in effects gained by co-administering ivermectin (Supporting Table S2).

The number of worm years and heavy infection case years averted due to preventive chemotherapy was higher in the higher transmission setting ([Table 2](#t0010){ref-type="table"}). In contrast, the number of prevalent case years averted was often larger in the lower transmission setting ([Table 2](#t0010){ref-type="table"}). This occurred because of the highly nonlinear relationship between mean worm burden and prevalence (a large proportion of worms are in a small proportion of individuals) ([@bb0235]). Consequently, at lower worm burdens, changes in mean worm load will often result in larger changes in prevalence (hence the number of prevalent case years averted can decrease as the level of transmission increases).

The relative increase in benefits yielded by ivermectin co-administration increased with the level of transmission intensity ([Table 3](#t0015){ref-type="table"}). In lower transmission settings the relative benefit in terms of averting heavy infections ([Table 3](#t0015){ref-type="table"}) was highly dependent on the assumed intensity threshold ([Table 1](#t0005){ref-type="table"}) i.e. the higher the intensity threshold, the easier it is to control heavy infections, and the lower the projected benefit of co-administering ivermectin. When using the higher intensity threshold, the pre-control prevalence of heavy infections was almost negligible for this transmission setting (hence there was a low benefit of ivermectin co-administration) (Supporting Fig. S2).Table 3Sensitivity of the relative increase in effects gained by co-administering ivermectin with albendazole to the transmission setting (in comparison with targeted albendazole monotherapy).Table 3Transmission intensityWorm years avertedPrevalent case years avertedHeavy infection case years averted --- lower threshold[a](#tf0010){ref-type="table-fn"}Heavy infection case years averted --- higher threshold[a](#tf0010){ref-type="table-fn"}Higher39%126%36%15%Lower11%26%4%1%[^4][^5]

3.2. Breaking transmission {#s0040}
--------------------------

When distributing albendazole monotherapy, breaking transmission even in the lower transmission setting was very difficult without a very high sustained coverage of Pre-SAC and SAC ([Fig. 5](#f0025){ref-type="fig"}).Fig. 5Number of years of annual treatment to achieve elimination of *T. trichiura* as a function of coverage of children versus adults. Two different transmission settings were explored; lower (R~0~ = 1.25), and higher (R~0~ = 1.75 --- fitted). Note that those under five years of age did not receive ivermectin and would only be treated with albendazole. ALB; Albendazole, IVM; Ivermectin. The corresponding results for mebendazole as shown in Supporting Fig. S4. Durations over ten years were not considered (marked as NA (not achievable)).Fig. 5

Ivermectin co-administration increased the feasibility of, and decreased the length of time required for, elimination ([Fig. 5](#f0025){ref-type="fig"}). As preventive chemotherapy coverage levels increased, feasibility of elimination improved and was possible in a shorter timeframe. The projections indicate that expanding treatment to include adults would only very slightly accelerate progress to elimination (by a maximum of two years). It should be noted that, even with ivermectin co-administration, elimination was often not possible within this timeframe in settings with high transmission.

3.3. Mebendazole--ivermectin co-administration {#s0045}
----------------------------------------------

A standalone treatment of mebendazole was assumed to have slightly higher efficacy compared to standalone albendazole ([@bb0240], [@bb0140]), and therefore it was projected to have a slighter larger impact ([Fig. 5](#f0025){ref-type="fig"} and Supporting Fig. S4). However, ivermectin co-administration still notably increased the programmatic effectiveness of a mebendazole-based programme and the general trends remained the same (Supporting Fig. S4). This was found to be particularly important in the context of achieving elimination --- as standalone mebendazole is still insufficient to break transmission in many settings, despite its higher efficacy (Supporting Fig. S4).

4. Discussion {#s0050}
=============

4.1. Controlling morbidity {#s0055}
--------------------------

Though targeting children for preventive chemotherapy with the current monotherapy treatments reduces *T. trichiura* worm burdens, the impact on *T. trichiura* was lower than on *A. lumbricoides* (despite their similar age intensity profiles) ([@bb0025], [@bb0030], [@bb0200], [@bb0205]).

In lower transmission settings and at a high coverage of Pre-SAC and SAC, monotherapy was projected to be effective in controlling heavy infections in children ([Fig. 3](#f0015){ref-type="fig"} and Supporting Fig. S2) --- though moderate intensity infections may still remain and have an impact on health ([Fig. 1](#f0005){ref-type="fig"}). However, these simulations indicate that in high transmission settings annual monotherapy may be insufficient to fully control heavy infections. Co-administering ivermectin increased the projected impact of the programme, particularly in high transmission settings (though some heavy infections remained when treatment was given annually).

Increasing the treatment frequency of albendazole monotherapy to twice a year was projected to have an equivalent impact to that of annual ivermectin co-administration. Biannual treatment is recommended by the WHO in high risk settings, if the resources are available --- which is not always the case ([@bb0250]). However, it is also important to recognise that increasing the treatment frequency of preventive chemotherapy results in a notable increase in programmatic costs and the resources needed for delivery ([@bb0210], [@bb0225]). Furthermore, biannual standalone treatment did not clear all heavy infections ([Fig. 3](#f0015){ref-type="fig"}). Consequently, if biannual treatment were feasible in a certain setting, co-administering ivermectin (for both rounds) would result in additional benefit ([Fig. 3](#f0015){ref-type="fig"} and [Table 2](#t0010){ref-type="table"}).

These findings were slightly more striking for programmes distributing albendazole than for mebendazole (as albendazole was assumed to have a slightly lower efficacy), but the general conclusions apply to both monotherapy treatments.

4.2. Breaking transmission {#s0060}
--------------------------

When using the current standalone treatments, elimination of *T. trichiura* was projected to be infeasible many settings ([Fig. 5](#f0025){ref-type="fig"}). This has particularly important consequences if STH control programmes shift their goals from control of morbidity to the interruption of transmission, as it indicates that without a change in approach, many endemic areas will be unable to meet new targets and treatment will have to be continued (which has important economic implications). Ivermectin co-administration greatly increased feasibility and lowered the timeframe of repeated preventive chemotherapy required for elimination ([Fig. 5](#f0025){ref-type="fig"}) --- which could potentially generate programmatic cost savings ([@bb0235]).

The coverage level of Pre-SAC and SAC was the most influential on feasibility of elimination. The projections indicate expanding treatment to adults through community-wide treatment would only very slightly accelerate progress to elimination in this setting ([Fig. 5](#f0025){ref-type="fig"}). The benefit of treating adults for *T. trichiura* was less than that estimated for *A. lumbricoides*, and much less than for hookworm, due to the assumed age profile of infection intensity (derived from a set of field studies in St Lucia ([@bb0065])) --- which determines the proportion of the total worm population in adults ([@bb0200], [@bb0025], [@bb0230]).

In the higher transmission setting our projections indicated elimination may not be feasible with preventive chemotherapy alone (even with ivermectin co-administration) ([Figs. 5](#f0025){ref-type="fig"} and [6](#f0030){ref-type="fig"})*.* This highlights the need for complementary control interventions such as water, sanitation and hygiene (WASH) ([@bb0190]) and improvements in health education.Fig. 6Mean intensity of infection in different age groupings (A) and the number of years of annual treatment to achieve elimination of *T. trichiura* with and without Pre-SAC being eligible for ivermectin co-administration (B). The age profile of infection intensity used to parameterise the model ([Fig. 1](#f0005){ref-type="fig"}) is taken from ([@bb0065]). ^†^Accounting for both the age profile of infection intensity and the assumed demography ([@bb0200]) yields an estimate of 25% of the worms occurring in Pre-SAC. Results in panel B) pertain to a fitted (higher) transmission setting (R~0~ = 1.75). Durations over ten years were not considered (marked as NA (not achievable)). ALB; Albendazole, IVM; Ivermectin.Fig. 6

4.3. The importance of preschool-aged children {#s0065}
----------------------------------------------

Our projections indicate that if ivermectin or another alternative treatment could be given to Pre-SAC, heavy infections would be further reduced ([Fig. 4](#f0020){ref-type="fig"} and Supporting Fig. S3) and the timeline to elimination would be shorter --- at least in settings where Pre-SAC have a high proportion of the overall worm burden ([@bb0065]) ([Fig. 6](#f0030){ref-type="fig"}). This analysis indicates that it would be advantageous for Pre-SAC to be eligible for any novel treatment strategy for *T. trichiura* ([@bb0015]), particularly if programmatic goals shift towards breaking transmission ([Fig. 6](#f0030){ref-type="fig"})*.*

4.4. Limitations {#s0070}
----------------

Due to the limited availability of data, there remains uncertainty surrounding the parameterisation of the key epidemiological processes of *T. trichiura* transmission models. This is particularly true for the strength of the density dependence acting on female worm fecundity --- which requires worm expulsion data to parameterise.

It is important to note that the projections regarding the added benefit of treating Pre-SAC and the limited impact of expanding mass treatment to include adults are highly dependent on the assumed age profile of infection intensity ([Figs. 1](#f0005){ref-type="fig"} and [6](#f0030){ref-type="fig"}) --- which is used to parameterise the relative exposure of different age groups to eggs in the environment. Though, the absence of alternative age stratified intensity datasets from other settings remains an important limitation of this study, the assumed profile and lower burden in adults ([Fig. 1](#f0005){ref-type="fig"}) is consistent with the overall pattern found by a recent systematic review of epidemiological surveys of STH in Southeast Asia ([Fig. 7](#f0035){ref-type="fig"}A) ([@bb0095]) and data from a study in Cameron ([@bb0155]) ([Fig. 7](#f0035){ref-type="fig"}B). That said there will be variations in this infection profile, and mass treatment of adults may be needed in some settings (furthermore pregnant women (a recognised risk group) may require treatment independent of this ([@bb0110])). More cross-sectional studies that measure both egg counts and worm burden are required to allow a range of different age profiles of infection intensity to be explored in the sensitivity analysis. It is important to note that converting EPG measurements to worm burden is not straightforward and would require a robust model of diagnostic sensitivity. This is an important area of future research for STH transmission models, as it will allow significantly more data to be used in model parameterization and validation.Fig. 7Observed age profiles of *T. trichiura* infection intensity in Southeast Asia (A) and Southwest Cameroon (B). Panel A contains EPG data from 11 studies (18 areas in four different countries) identified by a systematic review of epidemiological surveys of STH in Southeast Asia ([@bb0095]) (compared to data from the St. Lucia study ([@bb0065])). Panel B reproduces that data provided by a study from Cameroon ([@bb0155]). EPG: eggs per gramme of faeces.Fig. 7

Within the model, a worm burden above an age specific threshold was used as a proxy for disease (a standard method in the published literature ([@bb0075], [@bb0225], [@bb0160])). However, it is important to acknowledge that these thresholds ([Table 1](#t0005){ref-type="table"}) are uncertain, and are likely to be influenced by a number of host specific factors such as nutritional status ([@bb0235], [@bb0050]). These results further highlight that the reduction in prevalence of infection is a poor effectiveness metric when evaluating the impact of preventive chemotherapy on morbidity (which is linked to heavy infections). Because the number of prevalent case years averted is often larger in lower transmission settings ([Table 2](#t0010){ref-type="table"}) this metric would indicate it is more cost-effective to treat in lower compared to higher transmission settings (the opposite to what is observed when using metrics based on intensity ([@bb0235])).

It should be noted that uncertainty surrounds the precise treatment efficacies against *T. trichiura* --- partly due to the limitations of the current widely used diagnostic tool of faecal egg examination ([@bb0165]). However, the relative increase in the treatment efficacy when co-administering ivermectin was parameterised based on randomized controlled trials ([@bb0130], [@bb0195]) and is supported by other studies ([@bb0040], [@bb0045]).

Furthermore, these projections do not account for any non-compliance to treatment and assume that everyone has an equal probability of taking each treatment. Consequently, the benefit of increasing the treatment frequency will probably be overestimated (as it does not account for individuals systematically missing both treatment rounds --- which can reduce the benefit of increasing the treatment frequency ([@bb0215])).

4.5. Research needs {#s0075}
-------------------

Ivermectin is currently donated for onchocerciasis and lymphatic filariasis control ([@bb0005]), but not directly for STH. Consequently, the actual financial cost of ivermectin and/or its potential economic value if it were to be donated for STH needs to be estimated to allow future cost-effectiveness analysis (an important gap for NTDs ([@bb0220], [@bb0225], [@bb0135])).

It is important to consider that the use of ivermectin against *T. trichiura* will also have additional beneficial effects against Strongyloides infection ([@bb0080]), residual levels of onchocerciasis and lymphatic filariasis ([@bb0175]), and against co-endemic ectoparasites (such as scabies) ([@bb0090], [@bb0115]).

Ivermectin co-administration is not the only potential solution for the limited efficacy of the standard treatments against *T. trichiura*, and there is ongoing research on other drugs/drug combinations (such as: triple dosing with standalone albendazole or mebendazole, pyrantel--oxantel ([@bb0010]), oxantel pamoate--albendazole ([@bb0195], [@bb0125]) and papaya cysteine proteinases ([@bb0145])). This analysis indicates it would be advantageous for Pre-SAC to be eligible for any new treatment combinations. Dynamic transmission models can be useful tools for comparing the impact of the different alternative drugs/combinations (not only for *T. trichiura*, but the other STH species as well). This will be important for gaining a comprehensive understanding of the impact of the different potential drugs on all of the STH.

An important programmatic consideration for treating continuously with drugs that do not effectively clear *T. trichiura* is the potential risk of drug resistance developing ([@bb0245], [@bb0170]). The use of drug combinations may be an important method for delaying or avoiding drug resistance (as using drugs with different modes of action can make it harder for resistance to develop and spread). This aspect should be an important consideration in the evaluation of the various potential treatment alternatives for *T. trichiura* ([@bb0085]). As STH programmes expand over the coming years, further research in methods for detecting resistance and controlling its spread is urgently needed ([@bb0245], [@bb0035]).

A positive finding of this study is that current lymphatic filariasis treatment programmes, which include community-wide ivermectin--albendazole combination therapy, may be having a large impact on *T. trichiura*. This is supported by observations in the field ([@bb0150]). For this reason, future studies into the impact that scale-down or completion of LF control programmes will have on *T. trichiura* in co-endemic areas is required. This will become increasingly important as lymphatic filariasis programmes move towards elimination.

4.6. Conclusion {#s0080}
---------------

Although the current STH programmes providing child-targeted preventive chemotherapy with annual standalone albendazole or mebendazole reduce *T. trichiura* worm burdens, the impact for children is much lower compared to what can be seen for the other STH ([@bb0200], [@bb0205], [@bb0025]). In addition, these simulations indicate that in high transmission settings the standard treatments may be insufficient to fully control prevalence of heavy infections. Co-administering ivermectin greatly increased the projected impact of the programme in these high transmission settings, particularly in settings where biannual treatment is not possible.

When using the current standalone treatments, breaking transmission was projected to be infeasible in most settings. Ivermectin co-administration greatly increased the feasibility of and timeframe for elimination. This has particularly important consequences if STH control programmes shift their goals to the interruption of transmission. However, the benefit of ivermectin co-administration is limited by the fact that Pre-SAC are mostly ineligible for ivermectin. It would advantageous for this age group to be made eligible for any novel treatment strategy against *T. trichiura*.
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[^1]: The lower thresholds are based on empirical observations of worm numbers associated with developmental deficits ([@bb0075]). The higher thresholds are more conservative values intended to reflect more serious clinical consequences and to provide a lower boundary to the estimate of morbidity ([@bb0075], [@bb0070]).

[^2]: Results assume 75% treatment coverage of Pre-SAC and SAC. Two different transmission settings were explored; lower (R~0~ = 1.25), and higher (R~0~ = 1.75 --- fitted). The analysis was performed with a ten year time horizon (comparing ten years of standalone treatment to ivermectin co-administration). Note that those under five years of age did not receive ivermectin and would only be treated with albendazole.

[^3]: The thresholds for heavy infection are presented in [Table 1](#t0005){ref-type="table"}.

[^4]: Results pertain to a targeted preventive chemotherapy programme treating Pre-SAC and SAC with 75% treatment coverage. Two different transmission settings were explored; lower (R~0~ = 1.25), and higher (R~0~ = 1.75 --- fitted). The analysis was performed with a ten year time horizon (i.e. comparing ten years of standalone treatment to ivermectin co-administration). Note that those under five years of age did not receive ivermectin and would only be treated with albendazole.

[^5]: The thresholds for heavy infection are presented in [Table 1](#t0005){ref-type="table"}.
